Brief: Neonc Technologies Holdings Expects Full Enrollment In Promising Phase 2A Trial Of Neo100-01 For Malignant Gliomas In September
14/04/2025 15:10
April 14 (Reuters) - Neonc Technologies Holdings Inc NTHI.O: NEONC TECHNOLOGIES HOLDINGS, INC. EXPECTS FULL ENROLLMENT IN PROMISING PHASE 2A TRIAL OF NEO100-01 FOR MALIGNANT GLIOMAS IN SEPTEMBER Source text: ID:nGNXb0wSDk Further company coverage: NTHI.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Neonc Technologies Holdings
See all newsBrief: Neonc Technologies, Department Of Health – Abu Dhabi Sign MoU To Advance Brain Cancer Research
Brief: NeOnc Technologies Announces $15 Mln Offering Priced At-The-Market
U.S. STOCKS ON THE MOVE-Sutro Biopharma, Humacyte, CoreWeave
U.S. STOCKS ON THE MOVE-Sutro Biopharma, Humacyte
U.S. STOCKS ON THE MOVE-Nebius Group, Lumentum Holdings